Calliditas Therapeutics AB (NAS:CALT)
$ 40.0001 -0.1599 (-0.4%) Market Cap: 1.08 Bil Enterprise Value: 1.10 Bil PE Ratio: 0 PB Ratio: 104.30 GF Score: 35/100

Q4 2022 Calliditas Therapeutics AB Earnings Call Transcript

Feb 23, 2023 / 01:30PM GMT
Release Date Price: $19.99 (+11.06%)
Operator

Welcome to the Calliditas Therapeutics Q4 report. (Operator Instructions) Now I will hand the conference over to the speakers CEO, Renee Aguiar-Lucander; CFO, Fredrik Johansson; Andrew Udell, President of North America; and Richard Philipson, CMO.

Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Welcome to the Calliditas Therapeutics Q4 report of 2022. I would ask you to turn the page and initially just bring your attention to our disclaimer page, -- this is just related to forward-looking statements, and I refer you to the company's reports and other filings, including those which contain risk factors and other relevant information. We can go to the next page. So thank you for joining us for this fourth quarter report of 2022, which concludes a very successful year for Calliditas in which we commercially launched the first ever approved medication IgA nephropathy in the U.S. There has been great interest from nephrologists for medication, which targets the pursued origin of the disease and which does

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot